Abstract
Purpose In spite of the development of numerous vaccines for the prevention of COVID-19 and approvement of several drugs for its treatment, there is still a great need in effective and inexpensive therapy of this disease. Pharmacological evidence suggesting the therapeutic potential of green tea catechins in amelioration/treatment of COVID19 is growing rapidly, however, there are only a few epidemiological studies addressing this possibility. The aim of this study was to provide update regarding ecological study assessing this issue as of January 2021.
Methods The methodological approach used in this report is similar to that described previously. Briefly, information about COVID-19 morbidity (defined as a total number of cases per million population) and mortality (defined as a total number of deaths per million population) for a specific date was directly obtained from Worldometers info. Coronavirus. Analysis was restricted to 134 countries or territories with at least 3 million population. Twenty-one of these countries/territories, with estimated per/capita green tea consumption above 150 g (annually), were considered as a group with the high consumption. Countries/territories with the estimated per/capita green tea consumption below 150 g (N=82) were considered as the group with low the consumption.
Results Pronounced differences in COVID-19 morbidity and mortality between groups of countries with high and low green tea consumption were found as of February 20, 2022. These differences were still observed in a subset of countries with HDI above 0.55. Moreover, in this restricted subset of countries, weak but statistically significant correlations between COVID-19 morbidity (or mortality) and per/capita green tea consumption were observed in a multiple regression model accounting for: population density, percentage of population aged above 65, and percentage of urban population.
Conclusion The obtained results provide additional, though indirect, support of the idea that green tea catechins can be useful for treatment/amelioration of COVID-19. These results are in line with emerging evidence from other studies, including pharmacological. Nevertheless, further research is necessary to directly validate or reject this idea.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
